A5026944544- Pharmaceutical Practices and Patient Outcomes
- Health and Medical Education
- Pharmaceutical studies and practices
- Health Sciences Research and Education
- Acute Kidney Injury Research
- Pharmacovigilance and Adverse Drug Reactions
- Anesthesia and Sedative Agents
- Cardiac, Anesthesia and Surgical Outcomes
- Pharmacological Effects and Toxicity Studies
- COVID-19 Clinical Research Studies
- Vitamin C and Antioxidants Research
- Cardiac Arrest and Resuscitation
- Psychology Research and Bibliometrics
- Electroconvulsive Therapy Studies
- Diet and metabolism studies
- Psychological Treatments and Disorders
- Healthcare Systems and Technology
- Business, Innovation, and Economy
- Educational Innovations and Technology
- Assisted Reproductive Technology and Twin Pregnancy
- Alcoholism and Thiamine Deficiency
- Pharmaceutical Economics and Policy
- Neonatal and Maternal Infections
- Public Health in Brazil
- Long-Term Effects of COVID-19
Universitat Autònoma de Barcelona
2022-2023
Ministerio de Salud Pública
2012-2022
Indra (Spain)
2020
Escuela Nacional de Salud Pública
2015
Centro de Aplicaciones Tecnológicas y Desarrollo Nuclear
2006-2011
Concomitant use of diuretics, renin-angiotensin-aldosterone system (RAAS) inhibitors, and non-steroidal anti-inflammatory drugs (NSAIDs) or metamizole, known as 'triple whammy' (TW), has been associated with an increased risk acute kidney injury (AKI). Nevertheless, there is still uncertainty on its impact in hospitalisation mortality. The aim the study was to analyse association between exposure TW for AKI, all-cause mortality need renal replacement therapy (RRT).
Introduction: The pandemic caused by SARS-CoV-2 has put the global scientific community in an accelerated pace of research for effective treatment COVID-19. Objective: To identify and evaluate drugs Latin American protocols pharmacological Method: evidence mega trial results available to date on most frequent medications are analyzed. Results: common national hydroxychloroquine, lopinavir/ritonavir, remdesivir. None that collect data from clinical studies, with except dexamethasone a small...
<ns4:p><ns4:bold>Background:</ns4:bold> “Triple whammy” (TW) refers to the simultaneous use of diuretics, renin-angiotensin-aldosterone system inhibitors and nonsteroidal anti-inflammatory drugs (NSAIDs). To date, risk developing acute kidney injury (AKI) associated this combination has not been deeply investigated. The objectives are analyze incidence AKI exposure “triple including all NSAIDs versus non-exposure combination. Secondarily, hospitalization, severe adverse events, requirement...
"Triple whammy" (TW) refers to the simultaneous use of diuretics, renin-angiotensin-aldosterone system inhibitors and nonsteroidal anti-inflammatory drugs (NSAIDs). To date, risk developing acute kidney injury (AKI) associated this combination has not been deeply investigated. The objectives are analyze incidence AKI exposure "triple including all NSAIDs versus non-exposure combination. Secondarily, hospitalization, severe adverse events, requirement renal replacement therapy mortality will...